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EXPERT COMMENTARYNeutrophil gelatinase–associated lipocalin: A promising biomarker
for detecting cardiac surgery–associated acute kidney injuryDinna N. Cruz, MD,a Claudio Ronco, MD,a and Nevin Katz, MDbAcute kidney injury is a common and significant problem that occurs in a wide variety of clinical settings. Cardiac surgery–
associated acute kidney injury continues to be a well-recognized complication of cardiac surgery with associated morbidity
and mortality. A lack of early biomarkers for acute kidney injury has prevented timely interventions to mitigate the effects of
acute kidney injury. Because serum creatinine is not a timely marker of acute kidney injury, it cannot be used to institute po-
tentially effective therapies to treat acute kidney injury in patients during phases when the injury is still potentially reversible.
Neutrophil gelatinase–associated lipocalin has been identified as a promising biomarker for early detection of acute kidney
injury. Several studies have shown that neutrophil gelatinase–associated lipocalin levels increase significantly in patients
with acute kidney injury 24 to 48 hours before an increase in serum creatinine is detectable. Recent studies suggest that mea-
surements of neutrophil gelatinase–associated lipocalin levels in patients at risk for cardiac surgery–associated acute kidney
injury can facilitate its early diagnosis and allow clinicians to implement therapeutic adjustments that have the potential to
reverse renal cellular damage and minimize further kidney injury.Acute kidney injury (AKI) encompasses a broad spectrum of
insults to the kidney and often leads to acute renal failure,
a rapid and sustained decrease in kidney function.1 AKI
typically leads to serum creatinine (SCr) levels increasing
by more than 50%. Despite improvements in clinical care,
AKI remains a serious problem with an increasing
incidence. It occurs in approximately 5% of hospitalized pa-
tients and more than 30% of patients in the intensive care
unit (ICU) and is associated with high morbidity and mortal-
ity rates.2 Despite advances in the techniques and technol-
ogy of cardiac surgery, AKI continues to be an important
complication.
The clinical manifestations of AKI vary from a minimal
but sustained reduction in glomerular filtration rate (GFR)
to anuric renal failure.3 Depending on severity and duration,
AKI can be linked to metabolic conditions, such as metabolic
acidosis, hyperkalemia, and changes in body fluid balance.
Furthermore, patients are susceptible to infectious complica-
tions and frequently develop anemia.4,5 AKI is associated
with poor outcomes of ICU patients1 and is independently
associated with mortality in critically ill patients.6 In particu-
lar, renal injury is frequent after cardiac surgery because of
renal hypoperfusion, reperfusion injury, hemodilution, and
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The Journal of Thoracic and Carand mortality, ranging from 1% to 7% of patients.7,8 In a car-
diothoracic surgery population and a cohort of hospitalized
patients, both groups had a lower baseline mortality com-
pared with general ICU patients, and even small changes
in SCr were associated with a worse outcome.9,10
In current clinical practice, the standard measure for renal
function is serum concentrations of creatinine. Production of
creatinine by skeletal muscle is proportional to muscle mass
and is relatively constant, which made creatinine a conve-
nient marker for kidney function; however, its potential for
early detection of AKI is limited.11REVIEW OF STUDIES
Limitations of Serum Creatinine and the Importance
of Early Detection of Acute Kidney Injury
The severe consequences of AKI spotlight the need for
early detection. To this end, many studies have shown that
SCr is a suboptimal indicator of acute changes in kidney
function.12,13 The accuracy of using SCr to measure AKI
is of particular concern during acute changes in glomerular
filtration because it might not be useful until steady-state
equilibrium has been reached, which may occur 2 to 3
days postinjury.2 In particular, there are specific problems
in using SCr after cardiopulmonary bypass (CBP) surgery.7
Creatinine levels can be unreliable because creatinine pro-
duction is reduced if patients become hypothermic as the re-
sult of decreased blood flow, or levels can be increased
because of muscle damage during surgery. In addition, dur-
ing CPB, patients are fluid loaded and a varying amount of
plasma water may be removed by hemofiltration. Because
of these factors, the initial post-cardiac surgery SCr concen-
trations are lower than the preoperative levels in the majority
of patients.7
Because SCr is not a timely marker of AKI, it cannot be
used to institute potentially effective therapies to treat AKI
in patients during phases when the injury is still potentiallydiovascular Surgery c Volume 139, Number 5 1101
TABLE 1. Properties of ideal acute kidney injury markers that would
Expert Commentary Cruz et alhave clinical utility2
Ideal characteristics for AKI biomarkers
 Noninvasive
 Highly sensitive for
early detection
 Specific for AKI
 Allow monitoring
of patient
 Rapidly quantifiable
 Reproducible using
standard assays
 Allow for risk stratification
 Allow for identification
of AKI subtypes
 Stable production rate
 Circulating levels unaffected
by pathologic changes
 Freely filtered at glomerulus
without tubular
reabsorption/secretion
AKI, Acute kidney injury.
11Abbreviations and Acronyms
AKI ¼ acute kidney injury
AUC ¼ area under the curve
CIN ¼ contrast-induced nephropathy
CPB ¼ cardiopulmonary bypass
CSA ¼ cardiac surgery–associated
GFR ¼ glomerular filtration rate
ICU ¼ intensive care unit
IL ¼ interleukin
KIM ¼ kidney injury molecule
NGAL ¼ neutrophil gelatinase–associated lipocalin
SCr ¼ serum creatininereversible. In particular, although hemodynamic changes
and other factors associated with cardiac surgery may cause
renal injury, the injury typically remains undetected because
an increase in SCr is only detected several days after sur-
gery.14 By that time, the injury may have fully evolved
and clinicians can only provide supportive treatment, such
as dialysis.
Even moderate degrees of kidney dysfunction pose
a significant risk of mortality and morbidity, further high-
lighting the consequence of early versus late diagnosis of
AKI. Early detection of AKI is imperative because it allows
for immediate institution of measures to prevent further
damage, allows for renal recovery before damage is irrevers-
ible, and sets into motion protocols designed to closely mon-
itor ongoing renal injury. Several studies have shown the
importance of early detection of AKI. Parsons and col-
leagues15 compared survival in patients who were initially
dialyzed when the blood urea nitrogen was between 120
and 150 mg/dL versus those not dialyzed until blood urea ni-
trogen reached 200 mg/dL. They found that patients with
earlier dialysis had a survival of 75% compared with 12%
in patients dialyzed later. In another study, Elahi and
colleagues16 found that early continuous renal replacement
therapy during the first day after surgery was associated
with a lower mortality of 22% compared with a 43% mor-
tality rate for treatment given 2.5 days after surgery. These
studies indicate that early response to renal injury may result
in improved health outcomes.
Promising Biomarkers for Early Detection of Acute
Kidney Injury
The association of morbidity and mortality with AKI de-
mands a search for novel, early biomarkers. Biomarkers of
AKI should be sensitive and specific, and allow early diag-
nosis of renal injury (Table 1). Ideally, such biomarkers
would also be useful for determining prognosis and identify-
ing the physical site of injury to facilitate differentiating AKI
from other forms of acute kidney disease.202 The Journal of Thoracic and Cardiovascular SurMany of the conventional urinary biomarkers tested for
early detection of AKI are neither specific nor sensitive17;
however, some novel biomarkers are more promising. In
this review, we present an overview of neutrophil gelati-
nase–associated lipocalin (NGAL), compare it with current
and emerging biomarkers, and present evidence of its bene-
ficial role in early detection of AKI.
Neutrophil Gelatinase–Associated Lipocalin
Human NGAL is expressed by neutrophils and various
epithelia, and in the renal proximal tubules.18 Human
NGAL seems to be a marker for stress because it is highly
expressed in cells after infections, inflammation, ischemia,
or neoplastic transformation.19–22 Because of its small size
and resistance to degradation, NGAL is easily detected in
the blood and urine.23,24 The potential utility of NGAL as
an AKI biomarker was recognized because it was one of
the earliest and most rapidly induced genes in the kidney af-
ter ischemic or nephrotoxic injury in animal models. Fur-
thermore, the NGAL protein is rapidly up-regulated in the
blood and urine post-AKI.23,25 In the following sections,
we discuss how NGAL compares with other promising bio-
markers of AKI, namely, cystatin C, kidney injury molecule
(KIM)-1, and interleukin (IL)-18.Cystatin C
Cystatin C, a cysteine protease inhibitor, is synthesized by
nucleated cells and steadily released into the blood.2 The di-
agnostic utility of cystatin C as an AKI biomarker was tested
in patients who were at high risk of developing AKI. Serum
cystatin C can predict AKI (area under the curve [AUC],
97%) 1 to 2 days earlier than SCr (AUC, 82%),26 and an in-
creased urine cystatin C level predicted the need for dialysis
(AUC, 75%) earlier than SCr.27 In a comparative study, se-
rum NGAL, cystatin C, creatinine, and urea values were
measured after cardiac surgery in 100 adult patients in the
ICU and at 24 hours postoperatively.28 For measures taken
on arrival in the ICU, serum NGAL and cystatin C were
of good predictive potential compared with creatinine andgery c May 2010
Cruz et al Expert Commentaryurea. Early postoperative measurements showed that both
serum NGAL and cystatin C were superior to SCr and
urea in the prediction of cardiac surgery–associated (CSA)
AKI and of prognostic value in this setting.
In another study of 72 adults undergoing elective cardiac
surgery, serum cystatin C and NGALwere not useful predic-
tors of AKI within 6 hours after surgery.29 In marked con-
trast, both urine cystatin C and NGAL were elevated in the
34 patients who later developed AKI, compared with those
with no injury. The urine NGAL levels at the time of ICU
arrival and the urine cystatin C levels 6 hours after ICU
admission were most useful for predicting AKI. This sug-
gested that urine cystatin C and NGAL are superior to con-
ventional and novel plasma markers in the early diagnosis
of CSA-AKI, and that urine NGAL was an earlier marker
than cystatin C for CSA-AKI.
Cystatin C seems to be a better marker for AKI than SCr;
however, urine NGAL is superior to cystatin C for earlier de-
tection of AKI. In addition, cystatin C is mainly a marker of
clearance, and serum concentrations may increase only after
the GFR begins to decrease. In contrast, NGAL is rapidly in-
duced in kidney tubule cells in response to ischemic injury,
and its early appearance in the urine and serum is indepen-
dent of the GFR but is highly predictive of a subsequent de-
cline in GFR.Kidney Injury Molecule 1
Another promising biomarker is KIM-1, a type-1 trans-
membrane glycoprotein that is highly expressed in proximal
tubule cells after ischemic and nephrotoxic injury.17 In
a study of 40 children undergoing cardiac surgery, urine
KIM-1 levels peaked 12 hours after injury (AUC, 0.83) in
patients with AKI30 and predicted the need for dialysis or
mortality in hospitalized patients (AUC, 0.61).31 KIM-1
seems to be more specific to ischemic or nephrotoxic kidney
injury than NGAL and is not significantly affected by
chronic kidney disease or urinary tract infections.2 Thus,
KIM-1 represents a sensitive and specific marker for AKI af-
ter CPB. Because NGAL and KIM-1 are increased in urine
early after injury, they may serve as temporally sequential
biomarkers for early detection of AKI, with NGAL being
most sensitive at the earliest time points and KIM-1 adding
significant specificity at slightly later time points.24Interleukin-18
Recent research has shown that IL-18, a proinflammatory
cytokine, is highly up-regulated and easily detected in the
urine after ischemic AKI in animal models.25 Both urine
IL-18 and NGAL were early, predictive, sequential AKI bio-
markers in children undergoing cardiac surgery and indepen-
dently associatedwith duration of AKI.32 In patients inwhom
AKI developed 2 to 3 days after surgery, urine NGALpeaked
at 25-fold within 2 hours and declined 6 hours after surgery.The Journal of Thoracic and CarHowever, urine IL-18 levels increased at 6 hours and peaked
at more than 25-fold at 12 hours after surgery (AUC, 0.75).
The role of early predictive markers for AKI after coronary
angiography and their correlationwith cardiac events has also
been investigated for contrast-induced nephropathy (CIN)
(defined as a 50% increase in SCr from baseline), which is
the third-leading cause of hospital-acquired AKI.33 Urine
IL-18 and NGAL levels were significantly increased in the
CIN group, but not in the control group (P<.05). Both urine
and plasma NGAL predicted CIN within 2 hours of contrast
administration.34 By using a cutoff value of 100 ng/mL, the
AUC for prediction of CINwas excellent for the 2-hour urine
NGAL (0.92) and the 2-hour plasma NGAL (0.91).34 IL-18
was able to predict onset of AKI 24 hours earlier than SCr
(P < .01), but the levels of IL-18 increased later than
NGAL. Receiver operating characteristic curve analysis
showed that both IL-18 and NGAL performed well in early
diagnosis of CIN compared with SCr (P< .05). This study
showed that urine IL-18 is well associated with later cardiac
outcomes in patients undergoing coronary angiography.33
In another comparative study, the concentrations of serum
NGAL, urine NGAL, and urine IL-18 were measured in 33
patients undergoing cardiac surgery at different time
points.35 Postoperative AKI developed in 27% of the pa-
tients, and diagnosis with SCr was only possible 12 to 48
hours after the operation. Urine NGAL and IL-18 (not serum
NGAL) levels were significantly increased in the AKI
group, peaking 2 to 4 hours after surgery. However, urine
NGAL resulted in better sensitivity and specificity than urine
IL-18 at the earliest time points.35 The authors concluded
that although both urine NGAL and urine IL-18 were
good predictors of CSA-AKI, urine NGAL enables earlier
detection of AKI.Clinical Utility of Neutrophil Gelatinase–Associated
Lipocalin as an Early Marker for Acute Kidney
Injury
A range of translational studies have been performed to
determine NGAL’s value as a novel biomarker for human
AKI. In a study of 71 children undergoing cardiac surgery
with CPB, both serum and urine NGAL increased by 10-
fold within 2 to 6 hours of the surgery in patients (28%)
in whom AKI developed.36 Both were powerful prognostic
markers of AKI, with an AUC of 0.998 for the 2-hour urine
NGAL and an AUC of 0.91 for the 2-hour plasma NGAL
measurement. This study showed that urine NGAL was
more sensitive than serum NGAL, and that both markers
were superior to SCr for the early detection of AKI. In addi-
tion, the 2-hour urine NGAL level represented a stronger in-
dependent predictor of clinical outcomes, such as duration of
AKI among cases.
The predictive power of NGAL has also been confirmed
in 81 adult patients in whom AKI developed after cardiacdiovascular Surgery c Volume 139, Number 5 1103
FIGURE 1. Box plots of urine NGAL and SCr levels by diagnostic groups.
A, Patients with AKI had significantly up-regulated mean urine NGAL
levels compared with patients with other types of kidney dysfunction. Little
overlap was present, except in 3 patients with chronic kidney disease and 1
patient with prerenal azotemia who had high urine NGAL levels. B, Patients
with AKI had significantly elevatedmean SCr levels comparedwith patients
with other types of kidney dysfunction; however, values overlapped among
the different categories of kidney function.39 (Reprinted with permission
from Nickolas TL, O’Rourke MJ, Yang J, et al.39) NGAL, Neutrophil gelat-
inase–associated lipocalin.
Expert Commentary Cruz et alsurgery.37 Mean urine NGAL peaked immediately and
remained significantly higher 3 and 18 hours after surgery.
Patients who did not experience AKI also had significant in-
creases in urine NGAL in the early postoperative period, but
to a lesser degree than those with AKI. The findings from
this study were validated in a larger adult population
(N¼ 426) who had undergone a large variety of cardiac sur-
geries.14 Urine NGALwas significantly greater than SCr im-
mediately after surgery in patients with AKI, whereas SCr
levels peaked 2 days later. SCr levels decreased immediately
after surgery irrespective of subsequent AKI, most likely
because of perioperative hemodilution. This suggests that re-
nal injury may not result in an increase in SCr until several
days later, but that increases in urine NGAL can be detected
immediately in this heterogenous population.14
Prognostic Role of Neutrophil Gelatinase–Associated
Lipocalin
The potential of NGAL to predict CSA-AKI is promising.
Early postoperative measurement of serum NGAL in adult
patients undergoing cardiac surgery was of good value in
identifying patients who acquired AKI after surgery and
had excellent prognostic value for the defined end points,
that is, the need for renal replacement therapy and in-hospi-
tal mortality. In a study of 196 children undergoing cardiac
surgery with CPB, urine NGAL levels increased 15-fold
within 2 hours and 25-fold at 4 and 6 hours after CPB.38
For the 2-hour urine NGAL measurement, the AUC was
0.95, the sensitivity was 0.82, and the specificity was 0.90
for prediction of AKI using a cutoff value of 100 ng/mL.
The authors demonstrated the superiority of NGAL over
SCr as a biomarker for AKI, because 2-hour urine NGAL
levels correlated with several key parameters, including
the severity and duration of AKI, length of hospital stay, di-
alysis requirement, and death.
In the studies mentioned thus far, patients were selected to
eliminate the presence of comorbidities and confounding
factors and to test a specific variable with clear timing,
such as postsurgery. In contrast, Nickolas and colleagues39
showed that urine NGAL levels identified the presence of
AKI in a broad patient sample with different mechanisms
of injury. In a cohort study of 635 patients, the prognostic
utility of urine NGAL was compared with conventional
and novel biomarkers in predicting AKI and its comorbid
conditions. The sensitivity and specificity of a single mea-
surement of urine NGAL were 0.9 and 0.995, respectively,
and urine NGAL levels were highly predictive of clinical
outcomes, including nephrology consultation, dialysis, and
ICU admission.39 NGALwas also shown to be a useful early
marker that helps to distinguish AKI from normal function,
prerenal azotemia, and chronic kidney disease and predicts
poor inpatient outcomes (Figure 1).
This study helped to establish the validity of NGAL by
demonstrating that urine NGAL levels remained highly1104 The Journal of Thoracic and Cardiovascular Surdiagnostic even when the timing of injury was unknown,
making NGAL potentially diagnostic for renal disease for
many clinical presentations.39 The study had some limita-
tions, however, because the patients came from a single cen-
ter. Therefore, it would be important to validate these
findings in other groups of patients from multiple centers.
DISCUSSION
On the basis of the current findings from the literature, we
recommend that baseline NGAL measurements be deter-
mined in all individuals undergoing cardiac surgery,
whereas sequential measurements should be carried out ingery c May 2010
TABLE 2. Clinical conditions causing high risk for cardiac surgery–
associated acute kidney injury
Clinical conditions
Preoperative estimated GFR<60 mL/min/1.73 m2
(see Table 3 for corresponding SCr values)
Preoperative left ventricular ejection fraction<35%
Emergency surgery
Cardiogenic shock
Acute myocardial infarction in the week preceding surgery
Left main coronary artery disease
Receiving diuretic or inotropic therapy for decompensated heart failure
CPB time>3 h
GFR, Estimated glomerular filtration rate; SCr, serum creatinine; CPB, cardiopulmo-
nary bypass.
Cruz et al Expert Commentaryhigh-risk patients. Table 2 lists some clinical conditions that
place patients at a high risk for CSA-AKI. It is recommended
that serial testing of NGAL should be conducted in patients
with these clinical conditions.
Although these clinical conditions do not uniformly result
in CSA-AKI, they are, individually and combined, well-rec-
ognized factors associated with low cardiac output, hypoten-
sion, and impairment of renal perfusion. The subsequent
occurrence of AKI cannot be predicted from the presence
of these factors or, as noted above, from monitoring SCr.
However, if serial NGAL testing is performed, the early di-
agnosis of CSA-AKI can be made, and early therapeutic ad-
justments instituted to minimize irreversible kidney injury
and shorten the time of postoperative recovery.
Chronic kidney disease, defined as an estimated GFR less
than 60 mL/min/1.73 m2, is an important risk factor. SCr
values that represent this level of estimated GFR are listed
in Table 3.
High-risk patients who have elevated NGAL values
should be managed by close monitoring in the ICU andTABLE 3. Creatinine values for an estimated glomerular filtration
rate of 60 mL/min/1.73 m2 (above these values, patients are
considered at high risk for cardiac surgery–associated acute kidney
injury)
Male Female
Age (y)
Black
(mg/dL)
Non-black
(mg/dL)
Black
(mg/dL)
Non-black
(mg/dL)
20–24 1.9 1.6 1.4 1.2
25–29 1.8 1.5 1.4 1.2
30–34 1.7 1.5 1.3 1.1
35–39 1.7 1.4 1.3 1.1
40–44 1.6 1.4 1.3 1.1
45–49 1.6 1.4 1.2 1.1
50–54 1.6 1.3 1.2 1.0
55–59 1.6 1.3 1.2 1.0
60–69 1.5 1.3 1.2 1.0
>70 1.5 1.3 1.1 1.0
Estimated GFR ¼ 60 (mL/min per 1.73 m2) ¼ 186 3 (SCr)1.154 3 (age)0.203 3
(0.742 if female) 3 (1.210 if black).
The Journal of Thoracic and Caravoidance of nephrotoxic agents (eg, radiocontrast agents,
nonsteroidal anti-inflammatory drugs, and aminoglyco-
sides), and a nephrology consultation should be considered.
CONCLUSIONS
AKI is a frequent and serious complication encountered
after cardiac surgery. The need for biomarkers for AKI has
been fueled in recent years by advances in technology and
a better understanding of the importance of early detection.
At present, the greatest clinical challenges in AKI are in the
ICU setting, where biomarkers can be instrumental in mak-
ing the early diagnosis of AKI so that appropriate manage-
ment strategies can be instituted before irreversible renal
damage occurs. Biomarkers also can provide a timely as-
sessment of the nature and severity of AKI to predict the
need for dialysis. During the course of AKI, biomarkers of-
fer an opportunity to monitor the effectiveness of treatment
and assess the overall prognosis. The use of biomarkers for
the early diagnosis of AKI has the potential to transform
management and resulting outcomes. The importance of
this development is reflected in several studies that suggest
SCr may be an insensitive and late marker for AKI. By the
time kidney dysfunction is detected by an increase in SCr,
clinical intervention may have little effect. In contrast, stud-
ies document the highly predictive nature of NGAL for the
detection and assessment of CSA-AKI in both children
and adults. Serial testing of NGAL in selected patients at
high-risk for CSA-AKI may facilitate its early diagnosis
and allow clinicians to implement opportune therapeutic ad-
justments to potentially reverse renal cellular damage that
has already occurred and minimize further kidney injury.
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